At Mundipharma EDO we are keen to expand our portfolio and further our ambition to make advances in cancer treatment for patients around the world with rare or relapsed/refractory (difficult-to-treat) cancer.
Mundipharma EDO conducts research with leading academic researchers and clinical specialists worldwide. If you have a potential partnering opportunity or are interested in finding out more, please contact email@example.com
Those interested in discussing potential new compounds or assets should visit Mundipharma International in the first instance.
Press return to search